1. Hadley ME, Haskell-Luevano C. The proopiomelanocortin system. Ann N Y Acad Sci 1999; 885: 1-21.
2.
Fernandes B, Cavaco-Paulo A, Matamá T. A comprehensive review of mammalian pigmentation: paving the way for innovative hair colour-changing cosmetics. Biology 2023; 12: 290.
3.
Carlson JA, Linette GP, Aplin A, et al. Melanocyte receptors: clinical implications and therapeutic relevance. Dermatol Clin 2007; 25: 541-57.
4.
Kennedy C, ter Huurne J, Berkhout M, et al. Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color. J Invest Dermatol 2001; 117: 294-300.
5.
Bastiaens MT, ter Huurne JA, Kielich C, et al.; Leiden Skin Cancer Study Team. Melanocortin-1 receptor gene variants determine the risk of nonmelanoma skin cancer independently of fair skin and red hair. Am J Hum Genet 2001; 68: 884-94.
6.
Brzoska T, Luger TA, Maaser C, et al. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev 2008; 29: 581-602.
7.
Sawyer TK, Sanfilippo PJ, Hruby VJ, et al. 4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proc Natl Acad Sci USA 1980; 77: 5754-8.
8.
al-Obeidi F, Hruby VJ, Hadley ME, et al. Design, synthesis, and biological activities of a potent and selective alpha-melanotropin antagonist. Int J Pept Protein Res 1990; 35: 228-34.
9.
Barnetson RS, Ooi TK, Zhuang L, et al. [Nle4-D-Phe7]-alpha-melanocyte-stimulating hormone significantly increased pigmentation and decreased UV damage in fair-skinned Caucasian volunteers. J Invest Dermatol 2006; 126: 1869-78.
10.
McNeil MM, Nahhas AF, Braunberger TL, Hamzavi IH. Afamelanotide in the treatment of dermatologic disease. Skin Therapy Lett 2018; 23: 6-10.
11.
https://www.ema.europa.eu/en/documents/product-information/scenesse-epar-product-information_en.pdf
12.
Wu J, Cotliar R. Afamelanotide: an orphan drug with potential for broad dermatologic applications. J Drugs Dermatol 2021; 20: 290-4.
13.
Minder EI, Barman-Aksoezen J, Schneider-Yin X. Pharmacokinetics and pharmacodynamics of afamelanotide and its clinical use in treating dermatologic disorders. Clin Pharmacokinet 2017; 56: 815-23.
14.
Wahlin S, Floderus Y, Stål P, Harper P. Erythropoietic protoporphyria in Sweden: demographic, clinical, biochemical and genetic characteristics. J Intern Med 2011; 269: 278-88.
15.
Ventura P, Brancaleoni V, Di Pierro E, et al. Clinical and molecular epidemiology of erythropoietic protoporphyria in Italy. Eur J Dermatol 2020; 30: 532-40.
16.
Wensink D, Wagenmakers MAEM, Langendonk JG. Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria. Expert Rev Clin Pharmacol 2021; 14: 151-60.
17.
Whatley SD, Ducamp S, Gouya L, et al. C-terminal deletions in the ALAS2 gene lead to gain of function and cause X-linked dominant protoporphyria without anemia or iron overload. Am J Hum Genet 2008; 83: 408-14.
18.
Chakraborty A, Muranjan M, Karande S, Kharkar V. Porphyrias: uncommon disorders masquerading as common childhood diseases. J Postgrad Med 2023; 69: 164-71.
19.
Raef HS, Rebeiz L, Leaf RK, et al. Light-related cutaneous symptoms of erythropoietic protoporphyria and associations with light sensitivity measurements. JAMA Dermatol 2023; 159: 204-8.
20.
Dickey AK, Naik H, Keel SB, et al.; Porphyrias Consortium of the Rare Diseases Clinical Research Network. Evidence-based consensus guidelines for the diagnosis and management of erythropoietic protoporphyria and X-linked protoporphyria. J Am Acad Dermatol 2023; 89: 1227-37.
21.
Heerfordt IM, Lerche CM, Philipsen PA, Wulf HC. Experimental and approved treatments for skin photosensitivity in individuals with erythropoietic protoporphyria or X-linked protoporphyria: a systematic review. Biomed Pharmacother 2023; 158: 114132.
22.
Lyons AB, Trullas C, Kohli I, et al. Photoprotection beyond ultraviolet radiation: a review of tinted sunscreens. J Am Acad Dermatol 2021; 84: 1393-7.
23.
Corbett MF, Herxheimer A, Magnus IA, et al. The long term treatment with beta-carotene in erythropoietic protoporphyria: a controlled trial. Br J Dermatol 1977; 97: 655-62.
24.
von Laar J, Stahl W, Bolsen K, et al. Beta-carotene serum levels in patients with erythropoietic protoporphyria on treatment with the synthetic all-trans isomer or a natural isomeric mixture of beta-carotene. J Photochem Photobiol B 1996; 33: 157-62.
25.
Zaynoun ST, Hunter JA, Darby FJ, et al. The treatment of erythropoietic protoporphyria. Experience with beta-carotene. Br J Dermatol 1977; 97: 663-8.
26.
Mathews-Roth MM, Pathak UA, Fitzpatrick TB, et al. Beta-carotene as an oral photoprotective agent in erythropoietic protoporphyria. JAMA 1974; 228: 1004-8.
27.
Collins P, Ferguson J. Narrow-band UVB (TL-01) phototherapy: an effective preventative treatment for the photodermatoses. Br J Dermatol 1995; 132: 956-63.
28.
Sivaramakrishnan M, Woods J, Dawe R. Narrowband ultraviolet B phototherapy in erythropoietic protoporphyria: case series. Br J Dermatol 2014; 170: 987-8.
29.
Wahlin S, Stal P, Adam R, et al.; European Liver and Intestine Transplant Association. Liver transplantation for erythropoietic protoporphyria in Europe. Liver Transpl 2011; 17: 1021-6.
30.
Wahlin S, Harper P. The role for BMT in erythropoietic protoporphyria. Bone Marrow Transplant 2010; 45: 393-4.
31.
Kim ES, Garnock-Jones KP. Afamelanotide: a review in erythropoietic protoporphyria. Am J Clin Dermatol 2016; 17: 179-85.
32.
Harms J, Lautenschlager S, Minder CE, Minder EI. An alpha-melanocyte-stimulating hormone analogue in erythropoietic protoporphyria. N Engl J Med 2009; 360: 306-7.
33.
Langendonk JG, Balwani M, Anderson KE, et al. Afamelanotide for erythropoietic protoporphyria. N Engl J Med 2015; 373: 48-59.
34.
Barman-Aksözen J, Nydegger M, Schneider-Yin X, Minder AE. Increased phototoxic burn tolerance time and quality of life in patients with erythropoietic protoporphyria treated with afamelanotide – a three years observational study. Orphanet J Rare Dis 2020; 15: 213.
35.
Biolcati G, Marchesini E, Sorge F, et al. Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria. Br J Dermatol 2015; 172: 1601-12.
36.
Wensink D, Wagenmakers MAEM, Barman-Aksözen J, et al. Association of afamelanotide with improved outcomes in patients with erythropoietic protoporphyria in clinical practice. JAMA Dermatol 2020; 156: 570-5.
37.
Ogasawara A, Ogawa K, Ide R, et al. Results from a first-in-human study of dersimelagon, an investigational oral selective MC1R agonist. Eur J Clin Pharmacol 2023; 79: 801-13.
38.
Burfield L, Rutter KJ, Thompson B, et al. Systematic review of the prevalence and incidence of the photodermatoses with meta-analysis of the prevalence of polymorphic light eruption. J Eur Acad Dermatol Venereol 2023; 37: 511-20.
39.
Duteil L, Queille-Roussel C, Aladren S, et al. Prevention of polymorphic light eruption afforded by a very high broad-spectrum protection sunscreen containing ectoin. Dermatol Ther 2022; 12: 1603-13.
40.
Gambichler T, Al-Muhammadi R, Boms S. Immunologically mediated photodermatoses: diagnosis and treatment. Am J Clin Dermatol 2009; 10: 169-80.
41.
Iannelli M, Passanisi S, Crisafulli G, et al. Long term treatment with omalizumab in adolescent with refractory solar urticaria. Ital J Pediatr 2021; 47: 195.
42.
Hershkovitz Y, Khanimov I, Rubin L, et al. Successful ligelizumab treatment of severe refractory solar urticaria. J Allergy Clin Immunol Pract 2023; 11: 2576-7.
43.
Haylett AK, Nie Z, Brownrigg M, et al. Systemic photoprotection in solar urticaria with a-melanocyte-stimulating hormone analogue [Nle4-D-Phe7]-a-MSH. Br J Dermatol 2011; 164: 407-14.
44.
Iwanowski T, Kołkowski K, Nowicki RJ, Sokołowska-Wojdyło M. Etiopathogenesis and emerging methods for treatment of vitiligo. Int J Mol Sci 2023; 24: 9749.
45.
Grimes PE, Hamzavi I, Lebwohl M, et al. The efficacy of afamelanotide and narrowband UV-B phototherapy for repigmentation of vitiligo. JAMA Dermatol 2013; 149: 68-73.
46.
Lim HW, Grimes PE, Agbai O, et al. Afamelanotide and nNarrowband UV-B phototherapy for the treatment of vitiligo a randomized multicenter trial. JAMA Dermatol 2015; 151: 42-50.
47.
Toh JJH, Chuah SY, Jhingan A, et al. Afamelanotide implants and narrow-band ultraviolet B phototherapy for the treatment of nonsegmental vitiligo in Asians. J Am Acad Dermatol 2020; 82: 1517-9.
48.
Böhm M, Ehrchen J, Luger TA. Beneficial effects of the melanocortin analogue Nle4-D-Phe7-α-MSH in acne vulgaris. J Eur Acad Dermatol Venereol 2014; 28: 108-11.
49.
Biolcati G, Aurizi C, Barbieri L, et al. Efficacy of the melanocortin analogue Nle4-D-Phe7-α-melanocyte-stimulating hormone in the treatment of patients with Hailey-Hailey disease. Clin Exp Dermatol 2014; 39: 168-75.
50.
https://www.clinuvel.com/wpcontent/uploads/2023/01/20230116CUV156FirstResults.pdf
